NASDAQ:ALGS Aligos Therapeutics Q4 2024 Earnings Results & Report $1.66 -0.44 (-20.95%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.03 (+1.51%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aligos Therapeutics missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released March 10, 2025. The company reported EPS of -$13.08 versus the -$2.63 consensus estimate, while revenue of $629 thousand topped the $433 thousand estimate by $196 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 10, 2025TimeBefore Market OpensConference Call9:30 AM ET Aligos Therapeutics EPS ResultsActual EPS-$13.08Consensus EPS -$2.63Beat/MissMissed by -$10.45One Year Ago EPS-$5.50EPS Beat Rate6 of last 8 quartersAligos Therapeutics Revenue ResultsActual Revenue$629 thousandExpected Revenue$433 thousandBeat/MissBeat by +$196.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Aligos Therapeutics Q4 2024 Earnings FAQ Did Aligos Therapeutics beat earnings estimates for Q4 2024? Aligos Therapeutics (NASDAQ:ALGS) reported earnings of -$13.08 per share for Q4 2024, missing the consensus estimate of -$2.63. The report was announced on Monday, March 10, 2025. What was Aligos Therapeutics' revenue for Q4 2024? Aligos Therapeutics reported revenue of $629 thousand for Q4 2024, against a consensus estimate of $433 thousand. Aligos Therapeutics Earnings HeadlinesAligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street ZenNovember 14 at 1:31 AM | americanbankingnews.comAligos Therapeutics (NASDAQ:ALGS) Research Coverage Started at Jefferies Financial GroupNovember 12, 2026 | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 16 at 1:00 AM | Profits Run (Ad)Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial ResultsNovember 6, 2026 | globenewswire.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Has Consensus Price Target of $38.50 According to BrokeragesNovember 6, 2026 | americanbankingnews.comAligos Therapeutics Presents Positive Data at The Liver Meeting® 2026November 5, 2026 | globenewswire.comSee More Aligos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email. Email Address About Aligos TherapeuticsAligos Therapeutics (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases. The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication. Aligos is focused on research and clinical development rather than marketing approved medicines. Its programs are investigational, and their development status may change as clinical testing and company priorities evolve.View Aligos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.